Monoclonal antibodies against tumor necrosis factor alpha (TNFα), such as infliximab (IFX) or adalimumab (ADA), are safe and effective in induction and maintenance of remission in moderate to severe pediatric Crohn’s disease (CD) and ulcerative colitis (UC) patients [5,6]. This evidence concerns the gene TNF and Crohn disease.